The Emergence of Prenatal Gene Therapy: An “Embedded Ethics” Ethnography investigating Clinical, Scientific and Societal Values

产前基因治疗的出现：研究临床、科学和社会价值的“嵌入式伦理学”民族志

• 批准号: 10428702
• 负责人: Julia E.H. Brown
• 金额: $ 15.39万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-08 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10428702
• 关键词: Affect; Animal Model; Area; Attention; Award; Bioethics; California; Child; Clinic; Clinical; Clinical Research; Collaborations; Communities; Complement; Complex; Data; Decision Making; Diagnosis; Diagnostic; Disease; Education; Ensure; Environment; Enzymes; Ethical Analysis; Ethics; Ethnography; Exercise; Feedback; Fetus; Foundations; Future; Gene therapy trial; Gene-Modified; Genes; Genetic; Genetic Diseases; Genome; Genomic medicine; Genomics; Goals; Health; Healthcare; Human Genetics; Infrastructure; Intervention; Interview; Knowledge; Maternal Mortality; Medical Genetics; Mentors; Mentorship; Methodology; Methods; Molecular; Morbidity - disease rate; National Human Genome Research Institute; Outcome; Parents; Pathway interactions; Patient Preferences; Patients; Phase I Clinical Trials; Politics; Pregnancy; Preventive; Preventive treatment; Process; Public Participation; Reproductive Health; Reproductive Technology; Research; Research Training; Sampling; San Francisco; Scholarship; Science; Scientific Advances and Accomplishments; Shapes; Site; Social Values; Social support; Strategic vision; Structure; Technology; Therapeutic; Thinking; Time; Training; Uncertainty; Universities; career; clinical decision-making; community consultation; community engagement; cost; design; education research; ethical legal social implication; experience; fetal; frontier; gene therapy; genetic counselor; genome editing; health care availability; health disparity; health equity; health inequalities; human genomics; improved; in utero; innovation; innovative technologies; knowledge translation; maternal morbidity; maternal risk; member; postnatal; pre-clinical; precision medicine; prenatal; prenatal therapy; programs; prospective; repaired; skills; social; social disparities; social inclusion; socioeconomics; stem cells; therapy development

Project Summary/Abstract Genomic medicine and U.S. healthcare have reached an inflection point, where the next wave of innovative technologies may alleviate or exacerbate existing health inequity. There are multiple ethical, legal and social implications (ELSI) of transitioning from precision diagnosis to preventive treatments for genetic disease in a societal context of significant scientific uncertainty and inequitable healthcare access. The implementation and ELSI research oversight of fetal gene therapy – until now a hypothetical exercise – will profoundly shape whether the NHGRI 2030 strategic vision for improved community stakeholder engagements and equitable genomic medicine can be realized. The proposed K99/R00 Award presents a significant opportunity to incorporate ELSI knowledge into the pioneering processes of fetal gene therapy by investigating three distinct levels of ethical concern for emergent fetal gene therapy: clinical, regulatory and societal. Through interdisciplinary training, mentorship, and collaborations with the University of California, San Francisco Center for Maternal-Fetal Precision Medicine (CMFPM), the Stanford Center for Biomedical Ethics (SCBE) and the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), this project pursues an ethnographic and “embedded ethics” approach to fetal gene therapy at a critical juncture in preventive precision medicine and ELSI research. This multi-sited study on the ELSI of fetal gene therapy will connect what happens in the clinic, and its regulatory infrastructures, with the larger-scale societal values that will need to be incorporated to achieve greater social inclusion. The proposed five-year training and research program prepares the candidate for independent ELSI scholarship in the field of preventive genomic medicine, by harnessing ethnographic skills to complement a K99 acquired education in human genetics and genomics, bioethics and community engagement methods. Three barriers to social inclusion are identified: 1) tensions between clinical and social utility; 2) a lack of empirical data on decision-making processes given uncertainty; and 3) equitable stakeholder engagements. These problems inform three specific aims of this proposal: 1) to describe the processes that inform decisions about fetal gene therapy and its ‘utility,’ according to clinicians and patients who are directly involved in the most promising fetal gene and molecular therapies at CMFPM (K99); 2) to document how uncertainty is managed in the clinic and explore how this is shaped by social values and socioeconomic supports (K99); and 3) to account for diverse, non-patient community views and the extent to which fetal gene therapy developments are or are not socially inclusive (R00). Education and research to fulfill these aims will advance understanding about the scientific, regulatory, clinical, patient, and societal values that drive fetal gene therapy innovations. With unique ethnographic access to the clinical frontier of fetal gene therapy, it will provide an understanding of the importance of social inclusion during the process of knowledge translation, decision-making, and value-making.

项目总结/摘要 基因组医学和美国医疗保健已经达到了一个转折点，下一波创新 技术可以减轻或加剧现有的健康不平等。有多种伦理的、法律的和社会的 在一个国家，从精确诊断向遗传疾病预防性治疗过渡的影响（ELSI） 社会背景下的重大科学不确定性和不公平的医疗保健机会。执行和 ELSI对胎儿基因治疗的研究监督--到目前为止还是一种假设性的练习--将深刻地塑造 NHGRI 2030战略愿景是否改善了社区利益相关者的参与和公平 可以实现基因组医学。拟议的K99/R00奖提供了一个重要的机会， 将ELSI知识纳入胎儿基因治疗的开创性过程，通过研究三种不同的 紧急胎儿基因治疗的伦理关注水平：临床，监管和社会。通过 跨学科培训、指导以及与加州大学旧金山弗朗西斯科中心的合作 母胎精准医学（CMFPM）、斯坦福大学生物医学伦理中心（SCBE）和 UCSF-斯坦福大学监管科学与创新卓越中心（CERSI），该项目追求 人类学和“嵌入伦理学”的方法，胎儿基因治疗在预防的关键时刻 精准医学和ELSI研究。这项关于胎儿基因治疗ELSI的多点研究将连接 诊所里发生的事情，以及它的监管基础设施，以及更大规模的社会价值， 以实现更大的社会包容性。拟议的五年培训和研究计划 准备在预防基因组医学领域的独立ELSI奖学金的候选人，通过 利用人种学技能来补充K99获得的人类遗传学和基因组学教育， 生物伦理和社区参与方法。社会包容的三个障碍被确定：1）紧张局势 临床和社会效用之间的关系; 2）缺乏关于决策过程的经验数据; （三）利益相关者公平参与。这些问题说明了这项建议的三个具体目标：1） 根据临床医生的说法， 以及直接参与CMFPM最有前途的胎儿基因和分子治疗的患者 (K99)2）记录临床中如何管理不确定性，并探讨社会价值观如何塑造这种不确定性 和社会经济支持（K99）;和3）考虑到不同的，非病人社区的意见和程度 胎儿基因治疗的发展是否具有社会包容性（R00）。教育及研究 实现这些目标将促进对科学，监管，临床，患者和社会的理解 推动胎儿基因治疗创新的价值观。通过独特的人种学方法， 基因治疗，它将提供一个社会包容的过程中的重要性的理解， 知识转化、决策和价值制定。